Free Trial

MaxCyte Q3 2023 Earnings Report

MaxCyte logo
$4.94 +0.19 (+4.00%)
As of 01/17/2025 04:00 PM Eastern

MaxCyte EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.10
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

MaxCyte Revenue Results

Actual Revenue
$8.01 million
Expected Revenue
$7.90 million
Beat/Miss
Beat by +$110.00 thousand
YoY Revenue Growth
N/A

MaxCyte Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

MaxCyte Earnings Headlines

BlackRock Increases Stake in MaxCyte, Inc.
Kickstart Your 2025 Financial Resolutions with Just $30
Happy New Year! As we welcome 2025, it’s the perfect time to set your financial goals and build a prosperous future. Ready to transform your investments and achieve your financial resolutions? Imagine generating a reliable income stream from stocks priced under $30. Our latest guide introduces straightforward options strategies tailored for everyday investors, helping you turn well-known companies like Ford and Intel into consistent monthly income sources.
MaxCyte (MXCT) Receives a Buy from Craig-Hallum
MaxCyte Preliminary Q4 Core Revenue Improves
See More MaxCyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MaxCyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MaxCyte and other key companies, straight to your email.

About MaxCyte

MaxCyte (NASDAQ:MXCT), a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

View MaxCyte Profile

More Earnings Resources from MarketBeat